The role of angiogenic factors in fibroid pathogenesis: Potential implications for future therapy

Human Reproduction Update

Volumn 20, Issue 2, 2014, Pages 194-216

  Tal, Reshef ^a   Segars, James H ^b  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Angiogenesis; Anti angiogenesis; Hypoxia; Uterine leiomyoma; Vasculature

Indexed keywords

ANGIOGENESIS; ANTI-ANGIOGENESIS; HYPOXIA; UTERINE LEIOMYOMA; VASCULATURE;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEIOMYOMA; MYOMETRIUM; NEOVASCULARIZATION, PATHOLOGIC; UTERINE NEOPLASMS; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84894197709     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmt042     Document Type: Article

References (304)

1. AdamJ, Hatipoglu E, O'Flaherty L,Ternette N, Sahgal N, Lockstone H, Baban D, NyeE, Stamp GW, Wolhuter K et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011;20:524-537.
2. Ahn WS, Kim KW, Bae SM, Yoon JH, Lee JM, Namkoong SE, Kim JH, Kim CK, Lee YJ, Kim YW. Targeted cellular process profiling approach for uterine leiomyoma using cDNA microarray, proteomics and gene ontology analysis. Int J Exp Pathol 2003; 84:267-279.
3. Aitken E, Khaund A, Hamid SA, Millan D, Campbell S. The normal human myometrium has a vascular spatial gradient absent in small fibroids. Hum Reprod 2006; 21:2669-2678.
4. AlamNA,Rowan AJ,WorthamNC,Pollard PJ, MitchellM,Tyrer JP, Barclay E, Calonje E, Manek S, Adams SJ, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003;12:1241-1252.
5. Alatas G, Aksoy E, Akarsu C, Yakin K, Bahceci M. The effect of uterine volume on uterine artery Doppler velocimetry in the myomatous state. Gynecol Obstet Invest 1997;43:55-59.
6. Anania CA, Stewart EA, Quade BJ, Hill JA, Nowak RA. Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding. Mol Hum Reprod 1997;3:685-691.
7. Arici A, Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril 2000;73:1006-1011.
8. Arslan AA, Gold LI, Mittal K, Suen TC, Belitskaya-Levy I, Tang MS, Toniolo P. Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod 2005;20:852-863.
9. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964-3972.
10. AstrupT, Beller FK, Glas P, Rasmussen J. Fibronolytic activity of the human uterine tube. Obstet Gynecol 1965;25:853-857.
11. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002; 296:1646-1647.
12. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100-107.
13. Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun LZ. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 2002;62:4690-4695.
14. Bandyopadhyay A, Wang L, Lopez-Casillas F, Mendoza V, Yeh IT, Sun L. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate 2005;63:81-90.
15. Baranova O, Miranda LF, Pichiule P, Dragatsis I, Johnson RS, Chavez JC. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci 2007;27:6320-6332.
16. Barbarisi A, Petillo O, Di Lieto A, Melone MA, Margarucci S, Cannas M, Peluso G. 17-beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. J Cell Physiol 2001;186: 414-424.
17. Bardella C, Olivero M, Lorenzato A, Geuna M, Adam J, O'Flaherty L, Rustin P, Tomlinson I, Pollard PJ, Di Renzo MF. Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism. Mol Cell Biol 2012;32:3081-3094.
18. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-165.
19. Boehm KD, Daimon M, Gorodeski IG, Sheean LA, Utian WH, Ilan J. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev 1990;27:93-101.
20. Bowden W, Skorupski J, Kovanci E, Rajkovic A. Detection of novel copy number variants in uterine leiomyomas using high-resolution SNP arrays. Mol Hum Reprod 2009;15:563-568.
21. Brandon DD, Bethea CL, Strawn EY, Novy MJ, Burry KA, Harrington MS, Erickson TE, Warner C, Keenan EJ, Clinton GM. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993;169:78-85.
22. Brown LF, Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe ML. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest 1997;76:245-255.
23. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004;18: 2893-2904.
24. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:1337-1340.
25. Bullock JJ, Mehta SL, Lin Y, Lolla P, Li PA. Hyperglycemia-enhanced ischemic brain damage in mutant manganese SOD mice is associated with suppression of HIF-1alpha. Neurosci Lett 2009;456:89-92.
26. Burbank F. Childbirth andmyomatreatment by uterine artery occlusion: do they share a common biology? J Am Assoc Gynecol Laparosc 2004;11:138-152.
27. Burn PR, McCall JM, Chinn RJ, Vashisht A, Smith JR, Healy JC. Uterine fibroleiomyoma: MR imaging appearances before and after embolization of uterine arteries. Radiology 2000;214:729-734
28. Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012; 206:211e211-219.
29. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
30. Carmeliet P,DorY,Herbert JM, Fukumura D, Brusselmans K,DewerchinM,NeemanM, Bono F, Abramovitch R, Maxwell P, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-490.
31. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265:7709-7712.
32. Casey R, Rogers PA, Vollenhoven BJ. An immunohistochemical analysis of fibroid vasculature. Hum Reprod 2000;15:1469-1475.
33. Catherino WH, Leppert PC, Stenmark MH, Payson M, Potlog-Nahari C, Nieman LK, Segars JH. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer 2004;40:204-217.
34. Cha PC, Takahashi A, Hosono N, Low SK, Kamatani N, Kubo M, Nakamura Y. A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids. Nat Genet 2011;43:447-450.
35. Charnock-Jones DS, SharkeyAM,Rajput-Williams J, Burch D, Schofield JP, Fountain SA, Boocock CA, Smith SK. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod 1993;48:1120-1128.
36. Chegini N, Zhao Y, Williams RS, Flanders KC. Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, TGF beta 3, and TGF beta type II receptor messenger ribonucleic acid and protein and contains [125I]TGF beta 1-binding sites. Endocrinology 1994; 135:439-449.
37. Chegini N, Luo X, Ding L, Ripley D. The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol 2003a;209:9-16.
38. Chegini N, Verala J, Luo X,XuJ, Williams RS. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. J Soc Gynecol Investig 2003b;10:161-171.
39. Chen W, Ohara N, Wang J, Xu Q, Liu J, Morikawa A, Sasaki H, Yoshida S, Demanno DA, Chwalisz K, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006;91:1296-1304.
40. Cheng Z, Xie Y, Dai H, Hu L, Zhu Y, Gong J. Unequal tissue expression of proteins from the PA/PAI system, myoma necrosis, and uterus survival after uterine artery occlusion. Int J Gynaecol Obstet 2008;102:55-59.
41. Chin BY, Mohsenin A, Li SX, Choi AM, Choi ME. Stimulation of pro-alpha(1)(I) collagen by TGF-beta(1) in mesangial cells: role of the p38 MAPK pathway. Am J Physiol Renal Physiol 2001;280:F495-F504.
42. Chobotova K, Muchmore ME, Carver J, Yoo HJ, Manek S, Gullick WJ, Barlow DH, Mardon HJ. The mitogenic potential of heparin-binding epidermal growth factor in the human endometrium is mediated by the epidermal growth factor receptor and is modulated by tumor necrosis factor-alpha. J Clin Endocrinol Metab 2002; 87:5769-5777.
43. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007;87:1399-1412.
44. Ciarmela P, Islam MS, Reis FM, Gray PC, Bloise E, Petraglia F, ValeW, Castellucci M. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update 2011;17:772-790.
45. Colgan TJ, Pron G, Mocarski EJ, Bennett JD, Asch MR, Common A. Pathologic features of uteri and leiomyomas following uterine artery embolization for leiomyomas. Am J Surg Pathol 2003;27:167-177.
46. CookJD,Walker CL. Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin Reprod Med 2004;22:105-111.
47. Costa B, Dettori D, Lorenzato A, Bardella C, Coltella N, Martino C, Cammarata C, Carmeliet P, Olivero M, Di Renzo MF. Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. FASEB J 2010;24:2680-2688.
48. Crabtree JS, Jelinsky SA, Harris HA, Choe SE, Cotreau MM, Kimberland ML, Wilson E, Saraf KA, Liu W, McCampbell AS, et al. Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res 2009;69:6171-6178.
49. Cramer SF,Mann L, Calianese E, Daley J, Williamson K. Association of seedlingmyomas with myometrial hyperplasia. Hum Pathol 2009;40:218-225.
50. Cui L, Ren Y, Yin H,Wang Y, Li D, Liu M, Zhu Y, LinW, Tang XD, Gui Y, et al. Increased expression of tuberin in human uterine leiomyoma. Fertil Steril 2011;95:1805-1808.
51. De Falco M, Staibano S, D'Armiento FP, Mascolo M, Salvatore G, Busiello A, Carbone IF, Pollio F, Di Lieto A. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. J Soc Gynecol Investig 2006;13:297-303.
52. DeLeoV,Morgante G, La Marca A, MusacchioMC,Sorace M, Cavicchioli C, Petraglia F. A benefit-risk assessment of medical treatment for uterine leiomyomas. Drug Saf 2002;25:759-779.
53. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584.
54. deSouza NM, Williams AD. Uterine arterial embolization for leiomyomas: perfusion and volume changes at MR imaging and relation to clinical outcome. Radiology 2002;222:367-374.
55. Dhingra S, Rodriguez ME, Shen Q, Duan X, Stanton ML, Chen L, Zhang R, Brown RE. Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications. Int J Clin Exp Pathol 2011;4:134-146.
56. Di LietoA,De Falco M, Staibano S, Iannotti F, Scaramellino M, SalvatoreG, Mansueto G, Granata P, Pontillo M, Pollio F, et al. Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) in uterine leiomyomas. Int J Gynecol Pathol 2003a;22:353-358.
57. Di Lieto A, Iannotti F, De Falco M, Staibano S, Pollio F, Ciociola F, De Rosa G. Immunohistochemical detection of insulin-like growth factor type I receptor and uterine volume changes in gonadotropin-releasing hormone analog-treated uterine leiomyomas. Am J Obstet Gynecol 2003b;188:702-706.
58. Di Lieto A, De Falco M, Mansueto G, De Rosa G, Pollio F, Staibano S. Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern. Steroids 2005a;70:95-102.
59. Di Lieto A, De Falco M, Pollio F, Mansueto G, Salvatore G, Somma P, Ciociola F, De Rosa G, Staibano S. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig 2005b;12:123-128.
60. Dixon D, He H, Haseman JK. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect 2000;108 (Suppl 5):795-802.
61. Dou Q, Zhao Y, Tarnuzzer RW, Rong H, Williams RS, Schultz GS, Chegini N. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J Clin Endocrinol Metab 1996;81:3222-3230.
62. Dye J, Lawrence L, Linge C, Leach L, Firth J, Clark P. Distinct patterns of microvascular endothelial cell morphology are determined by extracellular matrix composition. Endothelium 2004;11:151-167.
63. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: a newparadigm for ischemic preconditioning. Circulation 2008;118:166-175.
64. Eggert SL, Huyck KL, Somasundaram P, Kavalla R, Stewart EA, Lu AT, Painter JN, Montgomery GW, Medland SE, Nyholt DR, et al. Genome-wide linkage and association analyses implicate FASN in predisposition to Uterine Leiomyomata. Am J Hum Genet 2012;91:621-628.
65. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003;101:243-250.
66. Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Open-label study of ultra-low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol 2009;146:215-218.
67. Eldar-Geva T, Meagher S, Healy DL, MacLachlan V, Breheny S, Wood C. Effect of intramural, subserosal, and submucosal uterine fibroids on the outcome of assisted reproductive technology treatment. Fertil Steril 1998;70:687-691.
68. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 1997; 16:1268-1278.
69. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107:43-54.
70. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003;9:1026-1032.
71. Farhi J, Ashkenazi J, Feldberg D, Dicker D, Orvieto R, Ben Rafael Z. Effect of uterine leiomyomata on the results of in-vitro fertilization treatment. Hum Reprod 1995; 10:2576-2578.
72. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 2002;99:229-234.
73. Farquhar CM, Harvey SA, Yu Y, Sadler L, StewartAW.Aprospective study of 3 years of outcomes after hysterectomy with and without oophorectomy. Am J Obstet Gynecol 2006;194:711-717.
74. Farrer-Brown G, Beilby JO, Tarbit MH. The vascular patterns in myomatous uteri. J Obstet Gynaecol Br Commonw 1970;77:967-975.
75. Faulkner RL. The blood vessels of the myomatous uterus. Am J Obstet Gynecol 1944; 47:185-197.
76. Fayed YM, Tsibris JC, Langenberg PW, Robertson AL Jr. Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin. Lab Invest 1989;60:30-37.
77. Fennessy FM, Tempany CM, McDannold NJ, So MJ, Hesley G, Gostout B, Kim HS, Holland GA, Sarti DA, Hynynen K, et al. Uterine leiomyomas: MR imaging-guided focused ultrasound surgery-results of different treatment protocols. Radiology 2007;243:885-893.
78. Fernig DG, Gallagher JT. Fibroblast growth factors and their receptors: an information network controlling tissue growth,morphogenesis and repair. Prog Growth Factor Res 1994;5:353-377.
79. Ferrara N, Davis-SmythT. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
80. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
81. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
82. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
83. Forssman L. Blood flow in myomatous uteri as measured by intra-arterial 133Xenon. Acta Obstet Gynecol Scand 1976a;55:21-24.
84. Forssman L. Distribution of blood flow in myomatous uteri as measured by locally injected 133Xenon. Acta Obstet Gynecol Scand 1976b;55:101-104.
85. Fraser HM, Duncan WC. SRB reproduction, fertility and development award lecture 2008. Regulation and manipulation of angiogenesis in the ovary and endometrium. Reprod Fertil Dev 2009;21:377-392.
86. Fraser HM, Lunn SF. Angiogenesis and its control in the female reproductive system. Br Med Bull 2000;56:787-797.
87. Fujii S, Konishi I, Horiuchi A, Orii A, Nikaido T. Mesenchymal cell differentiation: speculation about the histogenesis of uterine leiomyomas. In: Brosens IA, Donnez J, Lunenfeld B (eds). Pathogenesis and Medical Management of Uterine Fibroids. New York: The Parthenon Publishing Group, 1999, 3-15.
88. Fujimoto J. Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas. Anticancer Res 2009;29:2665-2669
89. Garg K, Tickoo SK, Soslow RA,Reuter VE. Morphologic features of uterine leiomyomas associated with hereditary leiomyomatosis and renal cell carcinoma syndrome: a case report. Am J Surg Pathol 2011;35:1235-1237.
90. Gargett CE, Rogers PA. Human endometrial angiogenesis. Reproduction 2001; 121:181-186.
91. Gentry CC, Okolo SO, Fong LF, Crow JC, Maclean AB, PerrettCW. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci (Lond) 2001;101:691-695.
92. Gross KL, Morton CC. Genetics and the development of fibroids. Clin Obstet Gynecol 2001;44:335-349.
93. Grubb RL 3rd, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, Torres-Cabala C, Glenn GM, Choyke P, Merino MJ, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007;177:2074-2079; discussion 2079-2080.
94. Gururaj AE, Belakavadi M, Venkatesh DA, Marme D, Salimath BP. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 2002;297:934-942.
95. Hague S, Zhang L, Oehler MK, Manek S, MacKenzie IZ, Bicknell R, ReesMC.Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density. Clin Cancer Res 2000;6:2808-2814.
96. Hague S, MacKenzie IZ, Bicknell R, Rees MC. In-vivo angiogenesis and progestogens. Hum Reprod 2002;17:786-793.
97. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47.
98. Harrison-Woolrych ML, Charnock-Jones DS, Smith SK. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab 1994;78:1179-1184.
99. Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, Smith SK. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab 1995; 80:1853-1858.
100. Hassan MH, Eyzaguirre E, Arafa HM, Hamada FM, Salama SA, Al-Hendy A. Memy I: a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice. Am J Obstet Gynecol 2008;199:156 e151-158.
101. Hassan M, Zhang D, Salama S, Hamada F, Arafa H, Fouad H,Walker C, Al-Hendy A. Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model. Gynecol Obstet Invest 2009;68:19-32.
102. Hassan MH, Salama SA, Zhang D, Arafa HM, Hamada FM, Fouad H, Walker CC, Al-Hendy A. Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril 2010;93:239-250.
103. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008;65:1631-1652.
104. Heldin CH. Platelet-derived growth factor-an introduction. Cytokine Growth Factor Rev 2004;15:195-196.
105. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-1316.
106. Heldin CH, Eriksson U, OstmanA.Newmembers of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 2002;398:284-290.
107. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999; 126:3047-3055.
108. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, Socci ND, Behrendt N, Ma L, Maki RG, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007; 13:748-753.
109. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991; 251:936-939.
110. Higashiyama S, Abraham JA, Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol 1993;122:933-940.
111. Hodge JC, Cuenco KT, Huyck KL, Somasundaram P, Panhuysen CI, Stewart EA, Morton CC. Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. Hum Genet 2009;125:257-263.
112. Hoekstra AV, Sefton EC, Berry E, Lu Z, Hardt J, Marsh E, Yin P, Clardy J, Chakravarti D, Bulun S, et al. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab 2009;94:1768-1774.
113. Hoffman PJ, Milliken DB, Gregg LC, Davis RR, Gregg JP. Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril 2004;82:639-649.
114. Hong T, Shimada Y, Uchida S, Itami A, Li Z, Ding Y, Kaganoi J, Komoto I, Sakurai T, Imamura M. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med 2001;8:141-148.
115. Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP. Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol 2007; 29:219-227.
116. Huang SC, Yu CH, Huang RT, Hsu KF, Tsai YC, Chou CY. Intratumoral blood flow in uterine myoma correlated with a lower tumor size and volume, but not correlated with cell proliferation or angiogenesis. Obstet Gynecol 1996;87:1019-1024.
117. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-7014.
118. Hwu YM, Li SH, Lee RK, Tsai YH, Yeh TS, Lin SY. Increased expression of platelet-derived growth factor C messenger ribonucleic acid in uterine leiomyomata. Fertil Steril 2008;89:468-471.
119. Hyder SM, Stancel GM. Regulation of VEGF in the reproductive tract by sex-steroid hormones. Histol Histopathol 2000;15:325-334.
120. Hyder SM, Huang JC,Nawaz Z, Boettger-Tong H, Makela S, ChiappettaC, Stancel GM. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect 2000;108 (Suppl 5):785-790.
121. Hyman KM, Seghezzi G, Pintucci G, Stellari G, Kim JH, Grossi EA, Galloway AC, Mignatti P. Transforming growth factor-beta1 induces apoptosis in vascular endothelial cells by activation of mitogen-activated protein kinase. Surgery 2002; 132:173-179.
122. Ignotz RA, Endo T, Massague J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem 1987;262:6443-6446.
123. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-557.
124. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005;8:143-153.
125. Ishikawa H, Shozu M, Okada M, Inukai M, Zhang B, Kato K, Kasai T, Inoue M. Early growth response gene-1 plays a pivotal role in down-regulation of a cohort of genes in uterine leiomyoma. J Mol Endocrinol 2007;39:333-341.
126. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al. Targeting of HIF-alpha to the Von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-472.
127. Jackson C. Matrix metalloproteinases and angiogenesis. Curr Opin Nephrol Hypertens 2002;11:295-299.
128. Jaffe RB. Importance of angiogenesis in reproductive physiology. Semin Perinatol 2000; 24:79-81.
129. Jaffer S, Shynlova O, Lye S.Mammalian target of rapamycin is activated in association with myometrial proliferation during pregnancy. Endocrinology 2009;150:4672-4680.
130. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-693.
131. Jha RC, Ascher SM, Imaoka I, Spies JB. Symptomatic fibroleiomyomata: MR imaging of the uterus before and after uterine arterial embolization. Radiology 2000; 217:228-235.
132. Joseph DS, Malik M, Nurudeen S, Catherino WH. Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil Steril 2010;93:1500-1508.
133. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000;275:1209-1215.
134. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002; 8:1253-1264.
135. Katsumori T, Kasahara T, Kin Y, Nozaki T. Infarction of uterine fibroids after embolization: relationship between postprocedural enhanced MRI findings and long-term clinical outcomes. Cardiovasc Intervent Radiol 2008;31:66-72.
136. Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, Ishimaru T, Masuzaki H. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 2010;25:642-653.
137. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
138. Klagsbrun M, Dluz S. Smooth muscle cell and endothelial cell growth factors. Trends Cardiovasc Med 1993;3:213-217.
139. Klauber N, Rohan RM, Flynn E, D'Amato RJ. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med 1997;3:443-446.
140. Klemke M, Meyer A, Nezhad MH, Bartnitzke S, Drieschner N, Frantzen C, Schmidt EH, Belge G, Bullerdiek J. Overexpression ofHMGA2in uterine leiomyomas points to its general role for the pathogenesis of the disease. Genes Chromosomes Cancer 2009; 48:171-178.
141. Kovacs KA, Lengyel F, Vertes Z, Kornyei JL, Gocze PM, Sumegi B, Szabo I, Vertes M. Phosphorylation of PTEN (phosphatase and tensin homologue deleted on chromosome ten) protein is enhanced in human fibromyomatous uteri. J Steroid Biochem Mol Biol 2007;103:196-199.
142. Kroencke TJ, Scheurig C, Poellinger A, Gronewold M, Hamm B. Uterine artery embolization for leiomyomas: percentage of infarction predicts clinical outcome. Radiology 2010;255:834-841.
143. Kurjak A, Kupesic-Urek S, Miric D. The assessment of benign uterine tumor vascularization by transvaginal color Doppler. UltrasoundMed Biol 1992;18:645-649.
144. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J. Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 1990;62:175-185.
145. Lametschwandtner A, Lametschwandtner U,Weiger T. Scanning electron microscopy of vascular corrosion casts-technique and applications: updated review. Scanning Microsc 1990;4:889-940; discussion 941.
146. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002;295:858-861. Laping NJ, Everitt JI, Frazier KS, Burgert M, Portis MJ, Cadacio C, Gold LI,Walker CL. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res 2007;13:3087-3099.
147. Laping NJ, Everitt JI, Frazier KS, Burgert M, Portis MJ, Cadacio C, Gold LI,Walker CL. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res 2007;13:3087-3099.
148. Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update 2012;18:682-702.
149. Laschke MW, Elitzsch A, Scheuer C, Vollmar B, Menger MD. Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril 2007;87:163-171.
150. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, Aaltonen LA. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 2001;98:3387-3392.
151. Lee BS, Nowak RA. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab 2001;86:913-920.
152. Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, Salovaara R, Herva R, Koivisto PA, Vierimaa O, Aittomaki K, Pukkala E, Launonen V, et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet 2006; 43:523-526.
153. Lei J, Jiang A, Pei D. Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta 1998; 1443:400-406.
154. Leppert PC, Catherino WH, Segars JH. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol 2006;195:415-420.
155. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16:137-161.
156. Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, Blocker W, Nieman LK. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129-1136.
157. Levy G, Hill MJ, Beall S, Zarek SM, Segars JH, Catherino WH. Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advances. J Assist Reprod Genet 2012;29:703-712.
158. Lewicka A, Osuch B, Cendrowski K, Zegarska J, Stelmachow J. Expression of vascular endothelial growth factor mRNA in human leiomyomas. Gynecol Endocrinol 2010; 26:451-455.
159. Li C, Guo B, Bernabeu C, Kumar S. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc Res Tech 2001;52:437-449.
160. Liang M, Wang H, Zhang Y, Lu S, Wang Z. Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol Ther 2006; 5:28-33.
161. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739-3743.
162. Liu J, Matulonis UA. Anti-angiogenic agents in ovarian cancer: dawn of a new era? Curr Oncol Rep 2011;13:450-458.
163. Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 2006;21:521-531
164. Lucerna M, Mechtcheriakova D, Kadl A, Schabbauer G, Schafer R, Gruber F, Koshelnick Y, Muller HD, Issbrucker K, Clauss M, et al. NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells. J Biol Chem 2003;278:11433-11440.
165. Luttun A,Dewerchin M, Collen D, Carmeliet P. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr Atheroscler Rep 2000;2:407-416.
166. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15:2675-2686.
167. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277: 55-60.
168. Makinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM, Aaltonen LA. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget 2011a;2:966-969.
169. Makinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011b;334:252-255.
170. Malik M, Catherino WH. Development and validation of a three-dimensional in vitro model for uterine leiomyoma and patient-matched myometrium. Fertil Steril 2012; 97:1287-1293.
171. Malik M,Webb J, Catherino WH. Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin Endocrinol (Oxf) 2008;69:462-470.
172. Malik M, Mendoza M, Payson M, Catherino WH. Curcumin, a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases fibronectin expression. Fertil Steril 2009;91:2177-2184.
173. Mangrulkar RS, Ono M, Ishikawa M, Takashima S, Klagsbrun M, Nowak RA. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. Biol Reprod 1995;53:636-646.
174. Marikovsky M, Breuing K, Liu PY, Eriksson E, Higashiyama S, Farber P, Abraham J, Klagsbrun M. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci USA 1993;90:3889-3893.
175. Marsh EE, Bulun SE. Steroid hormones and leiomyomas. Obstet Gynecol Clin North Am 2006;33:59-67.
176. Maruo T, Ohara N,Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 2004;10:207-220.
177. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990; 6:597-641. Masson N, Willam C, Maxwell PH, PughCW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. Embo J 2001;20:5197-5206.
178. Masson N, Willam C, Maxwell PH, PughCW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. Embo J 2001;20:5197-5206.
179. Masuda H, Kalka C, Takahashi T, Yoshida M,Wada M, Kobori M, Itoh R, Iwaguro H, Eguchi M, Iwami Y, et al. Estrogen-mediated endothelial progenitor cell biology and kinetics for physiological postnatal vasculogenesis. Circ Res 2007;101:598-606.
180. Matsuo H, Kurachi O, Shimomura Y, Samoto T, Maruo T. Molecular bases for the actions of ovarian sex steroids in the regulation of proliferation and apoptosis of human uterine leiomyoma. Oncology 1999;57 (Suppl 2):49-58.
181. MattaWH, Stabile I, ShawRW, Campbell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin. Fertil Steril 1988;49:1083-1085.
182. Mayer A, Hockel M, Wree A, Leo C, Horn LC, Vaupel P. Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia. Cancer Res 2008; 68:4719-4726.
183. Mayer A, Hoeckel M, vonWallbrunn A, Horn LC, Wree A, Vaupel P. HIF-mediated hypoxic response is missing in severely hypoxic uterine leiomyomas. Adv Exp Med Biol 2010;662:399-405.
184. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 2009;50:1140-1151. McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, Rajkovic A. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One 2012; 7:e33251.
185. McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, Rajkovic A. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One 2012; 7:e33251.
186. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393:333-339. Mehta VB, Besner GE. HB-EGF promotes angiogenesis in endothelial cells via PI3-kinase and MAPK signaling pathways. Growth Factors 2007;25:253-263.
187. Mehta VB, Besner GE. HB-EGF promotes angiogenesis in endothelial cells via PI3-kinase and MAPK signaling pathways. Growth Factors 2007;25:253-263.
188. Miller MJ, Martinez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, Cuttitta F. Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. J Biol Chem 1996;271:23345-23351.
189. Naganuma Y, Choijamts B, Shirota K, Nakajima K, Ogata S, Miyamoto S, Kawarabayashi T, Emoto M. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Sci 2011;102:1545-1552.
190. Nap AW, Griffioen AW, Dunselman GA, Bouma-Ter Steege JC, Thijssen VL, Evers JL, Groothuis PG. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004;89:1089-1095.
191. Nikitenko LL, MacKenzie IZ, Rees MC, Bicknell R. Adrenomedullin is an autocrine regulator of endothelial growth in human endometrium. Mol Hum Reprod 2000; 6:811-819.
192. Nikitenko LL, Cross T, Campo L, Turley H, Leek R, Manek S, Bicknell R, Rees MC. Expression of terminally glycosylated calcitonin receptor-like receptor in uterine leiomyoma: endothelial phenotype and association with microvascular density. Clin Cancer Res 2006;12:5648-5658.
193. Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999;14:2844-2850.
194. Norian JM, Malik M, Parker CY, Joseph D, Leppert PC, Segars JH, Catherino WH. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci 2009;16:1153-1164.
195. Nowak RA. Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors. Environ Health Perspect 2000;108 (Suppl 5):849-853.
196. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-328.
197. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
198. Oehler MK, Norbury C, Hague S, Rees MC, Bicknell R. Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene 2001;20:2937-2945.
199. Oehler MK, Hague S, Rees MC, Bicknell R. Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 2002;21:2815-2821.
200. Ohara N, Morikawa A, Chen W, Wang J, DeManno DA, Chwalisz K, Maruo T. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod Sci 2007;14:20-27.
201. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:571-588.
202. Olufowobi O, Sharif K, Papaionnou S, Neelakantan D,MohammedH, Afnan M. Are the anticipated benefits of myomectomy achieved in women of reproductive age? A 5-year review of the results at a UK tertiary hospital. J Obstet Gynaecol 2004; 24:434-440.
203. Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N, Fang L, Lee SW. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 2004;64:5283-5290.
204. Ono M, Maruyama T, Masuda H, Kajitani T, Nagashima T, Arase T, Ito M, Ohta K, Uchida H, Asada H, et al. Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci USA 2007;104:18700-18705.
205. Ono M, QiangW, Serna VA, Yin P, Coon JS.t, Navarro A, Monsivais D, Kakinuma T, Dyson M, Druschitz S, et al. Role of stem cells in human uterine leiomyoma growth. PLoS One 2012;7:e36935.
206. Pambuccian CA, Oprea GM, Lakatua DJ. Reduced expression of early growth response-1 gene in leiomyoma as identified by mRNA differential display. Gynecol Oncol 2002;84:431-436.
207. Patyna S, Haznedar J, MorrisD, Freshwater K, Peng G, Sukbuntherng J, Chmielewski G, Matsumoto D. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 2009;86:204-213.
208. Pauli SA, Tang H, Wang J, Bohlen P, Posser R, Hartman T, Sauer MV, Kitajewski J, Zimmermann RC. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 2005;146:1301-1311.
209. Peddada SD, Laughlin SK, Miner K, Guyon JP, Haneke K, Vahdat HL, Semelka RC, Kowalik A, Armao D, Davis B, et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci USA 2008; 105:19887-19892.
210. Pekonen F, Nyman T, Rutanen EM. Differential expression of keratinocyte growth factor and its receptor in the human uterus. Mol Cell Endocrinol 1993; 95:43-49.
211. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001; 86:346-355.
212. Pollard P,Wortham N, Barclay E, Alam A, Elia G, Manek S, Poulsom R, Tomlinson I. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 2005a;205:41-49.
213. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E,Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005b;14:2231-2239.
214. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997;272:7151-7158.
215. Poncelet C, Madelenat P, Feldmann G, Walker F, Darai E. Expression of von Willebrand's factor, CD34, CD31, and vascular endothelial growth factor in uterine leiomyomas. Fertil Steril 2002;78:581-586.
216. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441:437-443.
217. Presta M. Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. J Cell Physiol 1988;137:593-597.
218. Quade BJ, Wang TY, Sornberger K, Dal Cin P, Mutter GL, Morton CC. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 2004;40:97-108.
219. Ramsey M. Anatomy of the human uterus. In: Chard T, Grudzinskas JG (eds). The Uterus. Cambridge, UK: Cambridge University Press, 1994, 18-29.
220. Rasila KK, Burger RA, Smith H, Lee FC, Verschraegen C. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer 2005;15: 710-726
221. Ravina JH, Herbreteau D, Ciraru-Vigneron N, Bouret JM, Houdart E, Aymard A, Merland JJ. Arterial embolisation to treat uterine myomata. Lancet 1995; 346:671-672.
222. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995;172:14-18.
223. Ren W, Korchin B, Lahat G, Wei C, Bolshakov S, Nguyen T, Merritt W, Dicker A, Lazar A, Sood A, et al. Combined vascular endothelial growth factor receptor/ epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin Cancer Res 2008; 14:5466-5475.
224. Reynolds LP, Redmer DA. Angiogenesis in the placenta. Biol Reprod 2001; 64:1033-1040.
225. Reynolds LP, Grazul-Bilska AT, Redmer DA. Angiogenesis in the female reproductive organs: pathological implications. Int J Exp Pathol 2002;83:151-163. Ribatti D. Endogenous inhibitors of angiogenesis: a historical review. Leuk Res 2009; 33:638-644.
226. Ribatti D. Endogenous inhibitors of angiogenesis: a historical review. Leuk Res 2009; 33:638-644.
227. Ribatti D, Conconi MT, Nico B, Baiguera S, Corsi P, Parnigotto PP, Nussdorfer GG. Angiogenic response induced by a cellular brain scaffolds grafted onto the chick embryo chorioallantoic membrane. Brain Res 2003;989:9-15.
228. Rider V, Carlone DL, Foster RT. Oestrogen and progesterone control basic fibroblast growth factor mRNA in the rat uterus. J Endocrinol 1997;154:75-84.
229. RisauW. Mechanisms of angiogenesis. Nature 1997;386:671-674.
230. Ross R, RainesEW,Bowen-PopeDF. The biology of platelet-derived growth factor. Cell 1986;46:155-169.
231. Rossi MJ, Chegini N, Masterson BJ. Presence of epidermal growth factor, platelet-derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology 1992;130:1716-1727.
232. Rotello RJ, Lieberman RC, Purchio AF, Gerschenson LE. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor beta 1 in cultured uterine epithelial cells. Proc Natl Acad Sci USA 1991;88:3412-3415.
233. Sampson JA. The blood supply of uterine myomata. Surg Gynecol Obstet 1912; XIV:15-234. Sanci M, DikisC, Inan S, Turkoz E, Dicle N, Ispahi C. Immunolocalization of VEGF,VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma. Acta Histochem 2011;113:317-325.
234. Sanci M, DikisC, Inan S, Turkoz E, Dicle N, Ispahi C. Immunolocalization of VEGF,VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma. Acta Histochem 2011;113:317-325.
235. Sanz-Ortega J, Vocke C, Stratton P, Linehan WM, Merino MJ. Morphologic and Molecular Characteristics of Uterine Leiomyomas in Hereditary Leiomyomatosis and Renal Cancer (HLRCC) Syndrome. Am J Surg Pathol 2013;37:74-80.
236. Sarkar K, Cai Z, Gupta R, Parajuli N, Fox-Talbot K, Darshan MS, Gonzalez FJ, Semenza GL. Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. Proc Natl Acad Sci USA 2012;109:10504-10509.
237. Satterwhite DJ, Moses HL. Mechanisms of transforming growth factor-beta 1-induced cell cycle arrest. Invasion Metastasis 1994;14:309-318.
238. Scheurig-Muenkler C, Wagner M, Franiel T, Hamm B, Kroencke TJ. Effect of uterine artery embolization on uterine and leiomyoma perfusion: evidence of transient myometrial ischemia on magnetic resonance imaging. J Vasc Interv Radiol 2010; 21:1347-1353.
239. Selak MA, Armour SM, MacKenzie ED, Boulahbel H,Watson DG, Mansfield KD, PanY, Simon MC, Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005;7:77-85.
240. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
241. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-634.
242. Sharp HT. Assessment of new technology in the treatment of idiopathic menorrhagia and uterine leiomyomata. Obstet Gynecol 2006;108:990-1003.
243. Shichiri M, Kato H, Doi M, Marumo F, HirataY. Induction of max by adrenomedullin and calcitonin gene-related peptide antagonizes endothelial apoptosis. Mol Endocrinol 1999;13:1353-1363.
244. Shimomura Y, Matsuo H, Samoto T, Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 1998;83:2192-2198.
245. Shinozaki K, Suominen E, Carrick F, Sauter B, Kahari VM, Lieber A, Woo SL, Savontaus M. Efficient infection of tumor endothelial cells by a capsid-modified adenovirus. Gene Ther 2006;13:52-59.
246. Shozu M, Murakami K, Segawa T, Kasai T, IshikawaH, Shinohara K, Okada M, Inoue M. Decreased expression of early growth response-1 and its role in uterine leiomyoma growth. Cancer Res 2004;64:4677-4684.
247. Shushan A, Rojansky N, Laufer N, Klein BY, Shlomai Z, Levitzki R, Hartzstark Z, Ben-Bassat H. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod 2004;19:1957-1967.
248. Shushan A, Ben-Bassat H, Mishani E, Laufer N, Klein BY, Rojansky N. Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril 2007;87:127-135.
249. Shynlova O, Oldenhof A, Dorogin A, Xu Q, Mu J, Nashman N, Lye SJ. Myometrial apoptosis: activation of the caspase cascade in the pregnant rat myometrium at midgestation. Biol Reprod 2006;74:839-849.
250. Shynlova O, Dorogin A, Lye SJ. Stretch-induced uterine myocyte differentiation during rat pregnancy: involvement of caspase activation. Biol Reprod 2010; 82:1248-1255.
251. Smith SK. Angiogenesis, vascular endothelial growth factor and the endometrium.Hum Reprod Update 1998;4:509-519.
252. Sosic A, SkupskiDW, Streltzoff J, Yun H, Chervenak FA. Vascularity of uterine myomas: assessment by color and pulsed Doppler ultrasound. Int J Gynaecol Obstet 1996; 54:245-250.
253. Sozen I, Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril 2002;78:1-12.
254. Sperandio S, Fortin J, Sasik R, Robitaille L, Corbeil J, de Belle I. The transcription factor Egr1 regulates the HIF-1alpha gene during hypoxia. Mol Carcinog 2009; 48:38-44.
255. Stewart L, Glenn GM, Stratton P, Goldstein AM, Merino MJ, Tucker MA, Linehan WM, Toro JR. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. Arch Dermatol 2008;144:1584-1592.
256. Suo G, Jiang Y, Cowan B,Wang JY. Platelet-derived growth factor C is upregulated in human uterine fibroids and regulates uterine smooth muscle cell growth. Biol Reprod 2009;81:749-758.
257. Surrey ES, Lietz AK, Schoolcraft WB. Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization-embryo transfer cycle outcome. Fertil Steril 2001;75:405-410.
258. Takeda T, Osuga K, Morishige K, Tasaka K, Nakamura H, Murata Y. Changes of plasma vascular endothelial growth factor level after uterine artery embolisation for leiomyomata. BJOG 2005;112:1437-1439.
259. Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium. Acta Obstet Gynecol Scand 1985; 64:307-309.
260. Tang XM, Dou Q, Zhao Y, McLean F, Davis J, Chegini N. The expression of transforming growth factor-beta s and TGF-beta receptor mRNA and protein and the effect of TGF-beta s on human myometrial smooth muscle cells in vitro. Mol Hum Reprod 1997;3:233-240.
261. Taniguchi Y, Morita I, Kubota T, Murota S, Aso T. Human uterine myometrial smooth muscle cell proliferation and vascular endothelial growth-factor production in response to platelet-derived growth factor. J Endocrinol 2001;169:79-86.
262. Tavassoli FA, Devilee P. Tumors of the Breast and Female Genital Organs- Pathology and Genetics. Lyon, France: WHO Classification of Tumours, IARC, 2003, 64-67; 231-232; 265-266.
263. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. The human gene for vascular endothelial growth factor multiple protein forms are encoded through alternative exon splicing J Biol Chem 1991;266:11947-11954.
264. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet2002;30:406-410
265. Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, Stewart L, Duray P, Tourre O, Sharma N, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003;73:95-106.
266. Torry RJ, Rongish BJ. Angiogenesis in the uterus: potential regulation and relation to tumor angiogenesis. Am J Reprod Immunol 1992;27:171-179.
267. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 2008;283:34495-34499.
268. Treloar SA, Do KA, Martin NG. Genetic influences on the age at menopause. Lancet 1998;352:1084-1085.
269. Triozzi PL, Borden EC. VB-111 for cancer. Expert Opin Biol Ther 2011;11:1669-1676.
270. Tsibris JC, Segars J, Coppola D, Mane S, Wilbanks GD, O'Brien WF, Spellacy WN. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril 2002;78:114-121.
271. Tsiligiannis SE, Zaitseva M, Coombs PR, Shekleton P, Olshansky M, Hickey M, Vollenhoven B, Rogers PA. Fibroid-associated heavy menstrual bleeding: correlation between clinical features, Doppler ultrasound assessment of vasculature, and tissue gene expression profiles. Reprod Sci 2013;20:361-370.
272. UlianaV, Marcocci E, Mucciolo M, Meloni I, Izzi C, Manno C, Bruttini M, Mari F, Scolari F, Renieri A, et al. Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2. Pediatr Nephrol 2011;26:717-724.
273. van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer 2005; 117:883-888.
274. Varghese BV, Koohestani F, McWilliams M, Colvin A, Gunewardena S, Kinsey WH, Nowak RA, Nothnick WB, Chennathukuzhi VM. Loss of the repressor REST in uterine fibroids promotes aberrant G protein-coupled receptor 10 expression and activates mammalian target of rapamycin pathway. Proc Natl Acad Sci USA 2013;110:2187-2192.
275. Vikhlyaeva EM, Khodzhaeva ZS, Fantschenko ND. Familial predisposition to uterine leiomyomas. Int J Gynaecol Obstet 1995;51:127-131.
276. Vincent KA, Feron O, Kelly RA. Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. Trends Cardiovasc Med 2002;12:362-367.
277. Viville B, Charnock-Jones DS, Sharkey AM, Wetzka B, Smith SK. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod 1997; 12:815-822.
278. Vollenhoven BJ, Herington AC, Healy DL. Epidermal growth factor and transforming growth factor-beta in uterine fibroids and myometrium. Gynecol Obstet Invest 1995;40:120-124.
279. Vott S, Bonilla SM, Goodwin SC, Chen G,Wong GC, Lai A, Yegul T, DeLeon M. CT findings after uterine artery embolization. J Comput Assist Tomogr 2000;24:846-848.
280. Walker WJ, Pelage JP. Uterine artery embolisation for symptomatic fibroids: clinical results in 400 women with imaging follow up. BJOG 2002;109:1262-1272.
281. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005; 308:1589-1592.
282. Walocha JA, Litwin JA, Miodonski AJ. Vascular system of intramural leiomyomata revealed by corrosion casting and scanning electron microscopy. Hum Reprod 2003;18:1088-1093.
283. WangXN,Das SK,DammD, Klagsbrun M, Abraham JA,DeySK. Differential regulation of heparin-binding epidermal growth factor-like growth factor in the adult ovariectomized mouse uterus by progesterone and estrogen. Endocrinology 1994; 135:1264-1271.
284. Wang H, Mahadevappa M, Yamamoto K,Wen Y, Chen B,Warrington JA, Polan ML. Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril 2003;80:266-276.
285. Wang J, Ohara N, Takekida S, Xu Q, Maruo T. Comparative effects of heparin-binding epidermal growth factor-like growth factor on the growth of cultured human uterine leiomyoma cells and myometrial cells. Hum Reprod 2005;20:1456-1465.
286. Wang J, Ohara N,Wang Z, ChenW, MorikawaA, Sasaki H, DeManno DA, Chwalisz K, Maruo T. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod 2006;21:1869-1877.
287. Wei JJ, Zhang XM, Chiriboga L, Yee H, Perle MA, Mittal K. Spatial differences in biologic activity of large uterine leiomyomata. Fertil Steril 2006;85:179-187.
288. Weichert W, Denkert C, Gauruder-Burmester A, Kurzeja R, Hamm B, Dietel M, Kroencke TJ. Uterine arterial embolization with tris-acryl gelatin microspheres: a histopathologic evaluation. Am J Surg Pathol 2005;29:955-961.
289. Weston G, Trajstman AC, Gargett CE, Manuelpillai U, Vollenhoven BJ, Rogers PA. Fibroids display an anti-angiogenic gene expression profile when compared with adjacent myometrium. Mol Hum Reprod 2003;9:541-549.
290. Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, Lawrence AC, Lumsden MA, Hapangama D, Williams AR, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008;93:4664-4671.
291. Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol 1980;55:20-24.
292. Wolanska M, Bankowski E. Fibroblast growth factors (FGF) in human myometrium and uterine leiomyomas in various stages of tumour growth. Biochimie 2006; 88:141-146.
293. Work LM, Ritchie N, Nicklin SA, Reynolds PN, Baker AH. Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control. Gene Ther 2004;11:1296-1300.
294. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484.
295. Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson ED, Maruo T. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005;90:953-961.
296. Xu Q, Ohara N, ChenW, Liu J, Sasaki H, Morikawa A, Sitruk-Ware R, Johansson ED, Maruo T. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006;21:2408-2416.
297. Yamagata Y, Maekawa R, Asada H, Taketani T, Tamura I, Tamura H, Ogane J, Hattori N, Shiota K, Sugino N. Aberrant DNA methylation status in human uterine leiomyoma. Mol Hum Reprod 2009;15:259-267.
298. Yan SF, Lu J, Zou YS, Soh-Won J, Cohen DM, Buttrick PM, Cooper DR, Steinberg SF, Mackman N, Pinsky DJ, et al. Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 1999;274:15030-15040.
299. Yang EY, Moses HL. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990;111:731-741.
300. Yeh J, Rein M, Nowak R. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata. Fertil Steril 1991;56:997-1000.
301. Yu L, Saile K, Swartz CD, He H, Zheng X, Kissling GE, Di X, Lucas S, Robboy SJ, Dixon D. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med 2008;14:264-275.
302. Zhang Q, Jia Z, Liu S, Zhang G, Xiao Z, Yang D, Gan L, Wang Z, Li Y. Efficient cage-opening cascade process for the preparation of water-encapsulated [60]fullerene derivatives. Org Lett 2009;11:2772-2774.
303. Zhang Y, Cao H, Hu YY, Wang H, Zhang CJ. Inhibitory effect of curcumin on angiogenesis in ectopic endometrium of rats with experimental endometriosis. Int J Mol Med 2011;27:87-94.
304. ZhaoY,HagueS,Manek S,Zhang L, Bicknell R,ReesMC.PCRdisplay identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non-estrogenic mechanism in the human endometrium. Oncogene 1998;16:409-415